Saturday 17 October 2026
Export BVS’s income statement to Excel — free account
Bioventus Inc.
BVS Healthcare Medical Devices
Bioventus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $568.1 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 3.76%, EPS grew 345.5%, free cash flow fell 25.1% and total debt fell 27.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
13.30
0.51
−3.69%
Follow BVS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
8 | 8 | 8 | 8 |
| 3.85% | 10.98% | 13.57% | 22.75% | ||
| 1.03% | 3.22% | 4.24% | 7.89% | ||
ROIC |
5.41% | 7.16% | 7.64% | 7.34% | |
Return on Tangible Assets |
5.34% | 16.92% | 23.15% | 43.36% | |
Average Days of Receivables |
84.42 | 82.44 | 76.33 | 86.82 | |
Free Cash Flow per Share |
0.80 | 1.08 | 1.50 | 1.39 | |
Free Cash Flow |
53.47 | 72.11 | 100.63 | 94.29 | |
Capital Expenditures |
(2.56) | (2.56) | (2.31) | (2.59) | |
| Other line items | |||||
Cash ROIC |
9.35% | 12.57% | 18.56% | 16.98% | |
Accounts Receivable Turnover |
4.47 | 4.44 | 4.83 | 4.30 | |
Accounts Payable Turnover |
8.36 | 10.40 | 8.34 | 8.21 | |
Inventory Turnover |
1.95 | 2.06 | 2.04 | 2.07 | |
Average Days of Payables |
53.50 | 22.17 | 48.65 | 40.41 | |
Days of Inventory on Hand |
193.29 | 166.82 | 168.28 | 159.70 | |
Tax Rate |
(0.19) | 0.06 | 0.03 | 0.59 | |
Research and Development Expense of Revenue |
2.20% | 2.13% | 2.01% | 1.99% | |
Selling, General and Administrative Expense of Revenue |
56.43% | 55.28% | 55.33% | 55.42% | |
Share Based Compensation of Revenue |
2.00% | 2.23% | 2.35% | 2.56% | |
Interest Coverage |
1.40 | 2.04 | 2.47 | 2.93 | |
Operating CF/Net income |
7.38 | 3.28 | 3.61 | 1.78 | |
Depreciation/Fixed assets |
2.08 | 2.15 | 2.18 | 2.20 | |
Capex/Depreciation |
(0.05) | (0.05) | (0.05) | (0.06) | |
Revenue per Share |
8.42 | 8.53 | 8.56 | 8.57 | |
Operating CF per Share |
0.84 | 1.12 | 1.53 | 1.43 | |
Capex per Share |
(0.04) | (0.04) | (0.03) | (0.04) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates